Results Of Phase 1 Clinical Trial Lead Way To Use Of New Class Of...

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

http://www.medicalnewstoday.com/releases/255882.php